Johnson & Johnson Sees Positive Trial Results for Tremfya
By Chris Wack
Johnson & Johnson said it saw positive topline results from its Phase 3 investigational study of Tremfya subcutaneous induction therapy in adult patients with moderately to severely active Crohn's disease.
The pharmaceutical company said the study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at week 12 as well as endoscopic response at week 12.
All remaining multiplicity-controlled secondary endpoints at week 12, week 24 and week 48 were statistically significant compared to placebo.
A separate Johnson & Johnson study evaluating the efficacy and safety of Tremfya subcutaneous induction therapy in ulcerative colitis is ongoing.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 20, 2024 08:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
13 Charts On the Market’s Q2 Turnaround
-
10 Top-Performing Dividend Stocks of Q2 2024
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations
-
Real Estate: Interest Rate Movements Drive Performance
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities